retatrutide triple agonist glp-1 gip glucagon receptor The Road towards Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and - An Update Targeting GLP-1, GIP & GCG

The oral version was previously available for diabetes management (under the brand name Rybelsus), but this new FDA approval specifically authorizes a high-dose oral formulation for chronic weight management

Retatrutide differs from other weight loss medicines partly because the glucagon receptor it activates is thought to increase energy expenditure and promote fat burning in addition to the appetite-suppressing effects of GLP-1 and GIP

No destinado al consumo humano

Gallup found that following a recorded peak high of around 40% in 2022, study results showed a modest decrease to 37% in 2025

Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis combining 177 randomized controlled trials with a median follow-up of 26 weeks